Valuation: Shionogi & Co., Ltd.

Capitalization 2,788B 17.51B 14.87B 13.73B 12.95B 24.02B 1,630B 24.43B 161B 63.08B 784B 65.7B 64.33B P/E ratio 2026 *
14.3x
P/E ratio 2027 * 13.2x
Enterprise value 2,621B 16.47B 13.98B 12.91B 12.17B 22.58B 1,532B 22.97B 151B 59.31B 737B 61.78B 60.49B EV / Sales 2026 *
5.21x
EV / Sales 2027 * 4.13x
Free-Float
90.79%
Yield 2026 *
2.02%
Yield 2027 * 2.29%
1 day-1.71%
1 week-4.48%
Current month-7.18%
1 month-7.31%
3 months+13.36%
6 months+34.22%
Current year+13.34%
1 week 3,215
Extreme 3215
3,406
1 month 3,215
Extreme 3215
3,758
Current year 2,800.5
Extreme 2800.5
3,758
1 year 2,162
Extreme 2162
3,758
3 years 1,906
Extreme 1906
3,758
5 years 1,812.67
Extreme 1812.6667
3,758
10 years 1,459.67
Extreme 1459.6667
3,758
Manager TitleAgeSince
Chief Executive Officer 66 30/06/2022
Chief Tech/Sci/R&D Officer 61 30/06/2022
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 66 30/06/2022
Director/Board Member 65 31/05/2025
Director/Board Member 64 31/05/2025
Change 5d. change 1-year change 3-years change Capi.($)
-1.71%-4.48%+36.04%+57.69% 17.51B
-0.11%-5.36%+23.01%+141.24% 809B
-1.73%-2.81%+52.39%+41.43% 565B
+0.27%-1.61%+21.73%+29.33% 370B
-0.43%-0.35%+24.06%+13.94% 320B
+0.10%-2.36%+46.88%+25.76% 312B
-2.07%-5.89%+51.01%+0.13% 285B
+0.16%-3.33%+29.87%+33.60% 286B
+0.34%-1.75%+23.62%+39.76% 189B
+1.50%+8.52%-33.04%-55.11% 180B
Average -0.06%-2.06%+27.56%+32.78% 333.19B
Weighted average by Cap. +0.27%-2.45%+30.25%+50.79%

Financials

2026 *2027 *
Net sales 503B 3.16B 2.68B 2.48B 2.34B 4.33B 294B 4.41B 29.04B 11.38B 141B 11.86B 11.61B 682B 4.29B 3.64B 3.36B 3.17B 5.88B 399B 5.98B 39.38B 15.43B 192B 16.08B 15.74B
Net income 195B 1.23B 1.04B 962M 907M 1.68B 114B 1.71B 11.28B 4.42B 54.93B 4.6B 4.51B 212B 1.33B 1.13B 1.04B 983M 1.82B 124B 1.86B 12.23B 4.79B 59.55B 4.99B 4.89B
Net Debt -167B -1.05B -889M -821M -774M -1.44B -97.46B -1.46B -9.62B -3.77B -46.89B -3.93B -3.85B 25.97B 163M 139M 128M 121M 224M 15.18B 228M 1.5B 588M 7.31B 612M 599M
Logo Shionogi & Co., Ltd.
Shionogi & Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The Company is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The Company provides products and services in Japan, Europe, North America, and other regions.
Employees
4,955
Date Price Change Volume
17/04/26 3,220.00 ¥ -1.71% 2,315,500
16/04/26 3,276.00 ¥ -0.70% 2,930,300
15/04/26 3,299.00 ¥ -0.84% 2,399,600
14/04/26 3,327.00 ¥ -1.42% 1,808,800
13/04/26 3,375.00 ¥ +0.12% 2,094,100
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
3,276.00JPY
Average target price
3,425.00JPY
Spread / Average Target
+4.55%

Quarterly revenue - Rate of surprise